Comparing Avita Medical (NASDAQ:RCEL) & Ambu A/S (OTCMKTS:AMBBY)

Ambu A/S (OTCMKTS:AMBBY – Get Free Report) and Avita Medical (NASDAQ:RCEL – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Institutional & Insider Ownership

27.7% of Avita Medical shares are held by institutional investors. 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Ambu A/S and Avita Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ambu A/S 8.18% 8.49% 6.75%
Avita Medical -56.96% N/A -78.53%

Volatility and Risk

Ambu A/S has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ambu A/S and Avita Medical”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ambu A/S $894.37 million 2.89 $90.19 million $0.30 36.67
Avita Medical $71.61 million 5.74 -$48.59 million ($1.44) -9.28

Ambu A/S has higher revenue and earnings than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Ambu A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ambu A/S and Avita Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ambu A/S 0 1 0 0 2.00
Avita Medical 1 1 5 0 2.57

Avita Medical has a consensus price target of $12.20, indicating a potential downside of 8.68%. Given Avita Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Avita Medical is more favorable than Ambu A/S.

About Ambu A/S

(Get Free Report)

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, CPR breathing barriers, video laryngoscopes, and training manikins. The company was founded in 1937 and is headquartered in Ballerup, Denmark.

About Avita Medical

(Get Free Report)

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.